Trial Search Results

Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF(Tumor Necrosis Factor)Therapy

A case-control study to evaluate the immunoinflammatory effect of prior exposure to anti-TNF therapy in patients with ulcerative colitis starting vedolizumab therapy

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Takeda

Stanford Investigator(s):


  • Drug: Vedolizumab


Inclusion Criteria:

   - adult patients (>18 years old)

   - clinical diagnosis of inflammatory bowel disease (Ulcerative Colitis)

   - clinical indication for biologic therapy

   - naive or failed anti-TNF therapy previously

Exclusion Criteria:

   - patients allergic or intolerant to vedolizumab,

   - past use of vedolizumab;

   - patient unable to give consent to enter the study

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
John Gubatan, MD